Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872621 | 0.91 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL4876571 | 0.90 | KCNH2 (0.37) | KCNH2HRH3 | |
| SCHEMBL4876592 | 0.88 | DPP4 (0.32) | KMT2AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4879016 | 0.87 | KMT2A (0.36) | KCNH2HRH3GRIN2BGRIN1KMT2A | |
| SCHEMBL3938006 | 0.86 | KCNH2 (0.38) | KCNH2HRH3KMT2AALDH1A1GAA | |
| SCHEMBL4868456 | 0.84 | ALDH1A1 (0.39) | GRIN2BKMT2AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4868339 | 0.84 | PTGS2 (0.33) | GRIN2BGRIN1KMT2AALDH1A1GAA | |
| SCHEMBL4871879 | 0.84 | GRIN2B (0.39) | GRIN2BGRIN1KMT2AALDH1A1GAA | |
| SCHEMBL4874739 | 0.84 | KMT2A (0.36) | KMT2AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4876257 | 0.83 | ALDH1A1 (0.34) | KMT2AALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | KCNH2 2647/4885HRH3 4258/4885GRIN2B 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.